Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Chandra Pasamonte

Podiatrist Chico, CA Doctor of Podiatric Medicine

NPI 1447207394 CMS profile 546383

1806 Foundation Ln, Chico, CA 95928

Open in the dashboard

General payments

$1,200

24 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Chandra Pasamonte of Chico, CA is reported in the CMS Open Payments database as having received $1,200 across 24 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 57th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $132 3
2024 General $344 3
2023 General $145 2
2021 General $244 5
2020 General $105 4
2019 General $231 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chandra Pasamonte
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Chandra Pasamonte were reported at $132. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Chandra Pasamonte Podiatrist median Middle half National median
2019 $231 $196 $72–$601 $163
2020 $105 $118 $38–$335 $114
2021 $244 $169 $57–$573 $132
2022 $0 $220 $74–$782 $149
2023 $145 $208 $71–$635 $160
2024 $344 $237 $87–$681 $164
2025 $132 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Zimmer Biomet Holdings, Inc. $338 4 payments
  2. Stryker Corporation $316 11 payments
  3. Organogenesis Inc. $250 2 payments
  4. Curonix LLC $132 3 payments
  5. MIMEDX Group, Inc. $96 1 payment
  6. Bioventus LLC $29 1 payment
  7. Smith+Nephew, Inc. $20 1 payment
  8. Osiris Therapeutics Inc. $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,200 24 payments
Products named General payments · program years 2019–2025
  1. ANCHORAGE $155 7 payments
  2. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $132 3 payments
  3. PURAPLY WOUND MATRIX $125 1 payment
  4. Affinity $125 1 payment
  5. NuShield $125 1 payment
  6. APLIGRAF $125 1 payment
  7. NOVACHOR $125 1 payment
  8. Puraply $125 1 payment
  9. Stratum Foot Plating System $123 1 payment
  10. Trabecular Metal (TM) Ankle $115 1 payment
  11. Other $338 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

59

Median for Podiatry: 160

Drug cost

$773

Median for Podiatry: $2,368

Branded share of claims

0%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cephalexin Generic 17 $563
Gabapentin Generic 42 $209

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$203,805

Of which drugs: $47

Medicare patients

383

Average age 75

Services billed

3,429

257 women, 126 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 46%
Diabetes 31%
Ischemic heart disease 19%
Osteoporosis 19%
Atrial fibrillation 18%
Chronic kidney disease 18%
Depression 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 34 38 $37
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 12 13 $9

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

24 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record